Company intelligence / Profile preview
JW CreaGene
Seongnam-si, Gyeonggi-do, South Koreajw-creagene.co.kr ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
JW CreaGene's lead candidate, CreaVax-HCC, is currently in Phase 3 clinical trials in South Korea for hepatocellular carcinoma. Previous results have shown the therapy to be safe and capable of inducing immune responses against liver cancer cells. Their glioblastoma program (CreaVax-BC) has completed Phase 1/2 trials.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Dendritic cell therapyCell therapyVaccineImmunotherapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Waseda UniversityJW PharmaceuticalOncoTherapy Science
Beyond the preview
Go deeper on JW CreaGene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW CreaGene.